DOWNSTREAM PROCESSING FEATURED ARTICLES
-
![2015 BPI Conference To Highlight Untapped Potential Of Protein A]( "Untapped Potential Of Protein A To Be Highlighted At BPI Conference")
Untapped Potential Of Protein A To Be Highlighted At BPI ConferencePete Gagnon, group manager for downstream processing at the Bioprocessing Technology Institute in Singapore, discusses his upcoming presentation at the 2015 BioProcess International (BPI) Conference. Protein A: the Fine Print, is one of several scheduled during the pre-conference symposia track, Innovation in Process and Product Development Technologies for Biopharmaceutical Development.
-
![nalgeneNunc]( "Synergies For Equipping The Single-Use Bioproduction Suite")
Synergies For Equipping The Single-Use Bioproduction Suite The growth of biopharmaceuticals entering the market has served to change the appearance of the bioproduction suite -
NIH Scientists Map First Steps In Flu Antibody Development
National Institutes of Health scientists have identified how a kind of immature immune cell responds to a part of influenza virus and have traced the path those cells take to generate antibodies that can neutralize a wide range of influenza virus strains. Study researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, were led by Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center. Their findings appear online in advance of print in Nature.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
![Bill whitford]( "Continuous Biomanufacturing: 10 Reasons Sponsors Hesitate")
Continuous Biomanufacturing: 10 Reasons Sponsors HesitateThe industry is abuzz with talk about continuous biomanufacturing (CB), and its virtues have been well described. Here we will look at some of the barriers or concerns perceived to limit its value to the industry. Justified or not, quite a few concerns have been expressed regarding the implementation of this new, rather disruptive technology.
-
Gemin X Pharmaceuticals: Finding A Drug's Mechanism Of Action
Gemin X, a pharmaceutical company focused on the discovery and development of advanced oncology
therapeutics, approached Metabolon to run a metabolism profile for one of their compounds—GMX1777. -
![Fig 1]( "Cultivation Of CHO Suspension Cells And SEAP Expression")
Cultivation Of CHO Suspension Cells And SEAP ExpressionThis application note describes the cultivation of CHO suspension cells in the wave-mixed Thermo Scientific HyPerforma Rocker Bioreactor with a maximum working volume of 5 L.
-
CD69 Expression On Activated Lymphocytes Is Stable In Streck's Cyto-Chex® BCT
The purpose of this study was to determine if the activation marker, CD69, is preserved and stable in whole blood samples collected in Cyto-Chex® BCT. Previous studies have demonstrated CD marker stability of whole blood samples collected in Cyto-Chex BCT for up to 7 days when stored at room temperature (18-22°C). By Jodi Alt, Ph.D
-
Automated Bioluminescent ADCC Reporter Bioassay Using Bioengineered Jurkat Cells
Pharmaceutical companies are increasingly exploring new biologic and biosimilar products, and thus increasing monoclonal antibody (mAb) immunotherapeutic research. By Tracy Worzella, Promega Corporation and Brad Larson, Applications Department, BioTek Instruments, Inc.
-
White Paper: Computrac® Moisture Analysis Made Simple When people aren’t feeling their best they often turn to medicine for relief from the symptoms that are associated with being ill. The public trusts that the products by pharmaceutical companies will not only make them feel better but will also not have harmful side effects.
DOWNSTREAM PROCESSING PRODUCTS
Time-to-clinic and time-to-market are two key factors in successful biopharmaceutical development.
ILC Dover brings a unique history and skill set to the biopharmaceutical industry, particularly single use biopharmaceutical powder handling and containment equipment.
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.